Company / PP&E (Net)
West Pharmaceutical Services PP&E (Net) History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest PP&E (Net)
$1.7B
FY2025
5-year range
$1.1B / $1.7B
FY2021-FY2025
Trend
+9.2%
vs FY2024
Sector context
#30 of 132
Health Care
What the data says
West Pharmaceutical Services's pp&e (net) of $1.7B is higher than 77% of companies in the Health Care sector (FY2025). PP&E (Net) has increased for 7 consecutive years, from $822M in FY2018 to $1.7B in FY2025.
Based on SEC 10-K filings.
$1.7B in FY2025 with a 5-year CAGR of +12.9%. Top quartile in the Health Care sector.
Improved from $1.4B to $1.7B over the past 2 years.
Health Care sector context is included.
PP&E (Net) over time
Growth rates
- 3-Year CAGR
- +14.2%
- 5-Year CAGR
- +12.9%
- 10-Year CAGR
- -
Sector benchmark
Top 23% in Health CareTop 23% of 132This company $1.7B Sector average $1.4B
▼
+20.3% above sector average
Key checks
Key Insights
- West Pharmaceutical Services's pp&e (net) has grown for 7 consecutive years.
- 5-year CAGR of +12.9%, indicating consistent growth.
- In FY2025, pp&e (net) increased 9.2% year-over-year.
- Ranks #30 out of 132 companies in the Health Care sector.
Company context
Key Data Points
- Altman Z-Score 3.45 (safe zone, above 2.9 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | PP&E (Net)Value | YoY GrowthYoY |
|---|---|---|
| FY2025 | $1.7B | +9.2% |
| FY2024 | $1.6B | +11.9% |
| FY2023 | $1.4B | +22.0% |
| FY2022 | $1.2B | +9.5% |
| FY2021 | $1.1B | +12.1% |
| FY2020 | $943.2M | +12.4% |
| FY2019 | $839.3M | +2.1% |
| FY2018 | $822.0M | -3.9% |
| FY2017 | $855.0M | +18.6% |
| FY2016 | $721.0M | +2.2% |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026